Analysis of blood concentrations and clinical application of risdiplam in patients with spinal muscular atrophy using ultra‐high performance liquid chromatography–tandem mass spectrometry
Biomedical Chromatography · 2024
DOI: 10.1002/bmc.5934 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, 2024. Verfasst von Xian Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, Muscular Atrophy, Spinal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: Collaborative Innovation Center for Clinical and Translational Science by the Chinese Ministry of Education & Shanghai (CCTS), Talent Project established by the Chinese Pharmaceutical Association Hospital Pharmacy department, Key Clinical Specialty Construction Project for the Clinical Pharmacy of Shanghai.
Abstract (Originalsprache)
Risdiplam, the first oral therapy approved for spinal muscular atrophy and made globally available in 2021, necessitates a highly sensitive and straightforward assay for therapeutic drug monitoring. This is crucial to manage potential toxicities linked to drug concentrations and supervise dosing regimens. A cutting‐edge ultra‐high performance liquid chromatography–tandem mass spectrometry bioassay for risdiplam in human serum has been developed. In this method, analytes were separated on a Phenomenex Kinetex XB C 18 column using a 6.5‐min gradient elution after a single‐step protein precipitation. MS detection was conducted via electrospray ionization in positive mode with selected reaction monitoring. The validated range for risdiplam was determined to be 1.95–125.00 ng/mL. The precision and accuracy of intra‐ and inter‐batch analyses were within ±15%. The novel method met all other established criteria. This assay holds promise for monitoring drug concentrations and guiding clinical decisions in patients with spinal muscular atrophy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.
- Department of Pharmacy, Chongqing Medical University, Chongqing, China.
- Department of Pharmacy, 363 Hospital, Sichuan, Chengdu, China.
ORCID-Profile: Xian Wu
Förderung
- Collaborative Innovation Center for Clinical and Translational Science by the Chinese Ministry of Education & Shanghai (CCTS)
- Talent Project established by the Chinese Pharmaceutical Association Hospital Pharmacy department
- Key Clinical Specialty Construction Project for the Clinical Pharmacy of Shanghai
Zitieren
APA
Wu, X., Lin, Z., Liu, Y., Liu, X., Yi, Z., Huang, X., & Zhang, J. (2024). Analysis of blood concentrations and clinical application of risdiplam in patients with spinal muscular atrophy using ultra‐high performance liquid chromatography–tandem mass spectrometry. Biomedical Chromatography. https://doi.org/10.1002/bmc.5934
Vancouver
Wu X, Lin Z, Liu Y, Liu X, Yi Z, Huang X, et al. Analysis of blood concentrations and clinical application of risdiplam in patients with spinal muscular atrophy using ultra‐high performance liquid chromatography–tandem mass spectrometry. Biomedical Chromatography. 2024. doi:10.1002/bmc.5934
BibTeX
@article{Wu2024,
author = {Wu, Xian and Lin, Zhiyan and Liu, Yan and Liu, Xinzhu and Yi, Zhenghong and Huang, Xiaohui and Zhang, Jian},
title = {Analysis of blood concentrations and clinical application of risdiplam in patients with spinal muscular atrophy using ultra‐high performance liquid chromatography–tandem mass spectrometry},
journal = {Biomedical Chromatography},
year = {2024},
doi = {10.1002/bmc.5934}
}
EUVIMED